Management of Spironolactone in Patients Admitted for UTI

Patient Assessment and Spironolactone Discontinuation

The American College of Cardiology (ACC) and American Heart Association (AHA) guidelines recommend discontinuing spironolactone in patients with potassium levels ≥5.0 mEq/L 1
The European Society of Cardiology (ESC) guidelines require immediate discontinuation of spironolactone in patients with potassium levels >5.5 mEq/L 3
Spironolactone should be discontinued in patients with creatinine levels >2.5 mg/dL in men or >2.0 mg/dL in women, as indicated by guidelines from the ACC/AHA 2
The use of spironolactone is contraindicated in patients with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m², according to the ACC/AHA guidelines 1, 4

The combination of spironolactone and ACE inhibitors increases the risk of hyperkalemia, with a reported rate of 24% in real-world patients, compared to 2% in clinical trials 1, 3
The mortality rate increases from 0.3 to 2 per 1,000 patients after widespread spironolactone adoption in population studies 1, 3
Patients on spironolactone with renal angiotensin-aldosterone system (RAAS) inhibitors have an increased risk of hyperkalemia, with a reported prevalence of 11.2% in outpatients 3

Potassium and creatinine levels should be rechecked within 2-3 days of spironolactone discontinuation, then again at 7 days, and monthly for 3 months, as recommended by the ESC guidelines 3, 2
Aggressive treatment of hyperkalemia is necessary if potassium levels exceed 6.0 mEq/L or if EKG changes develop, such as peaked T waves, widened QRS, or loss of P waves 3

Spironolactone can be restarted after UTI resolution if potassium levels fall below 5.0 mEq/L and eGFR improves above 30 mL/min/1.73 m², as indicated by the ACC/AHA guidelines 2, 3
The restart dose should be reduced to 12.5 mg daily or every other day, not the previous dose, according to the ACC/AHA guidelines 1, 2

Continuing spironolactone in patients with acute illness can fundamentally change the risk-benefit calculation, and should be avoided, as recommended by the ACC/AHA guidelines 1
Assuming normal potassium levels on admission can be misleading, as potassium can rise rapidly during acute illness, especially with nephrotoxic antibiotics 1
Restarting spironolactone at discharge without documented potassium levels <5.0 mEq/L can increase the risk of adverse events, and should be avoided, according to the ACC/AHA guidelines 1, 2

Potassium binders, such as patiromer or sodium zirconium cyclosilicate, can be considered to enable continuation of spironolactone if clinically necessary, as recommended by the ESC guidelines 3, 2
Increasing loop diuretic doses can enhance renal potassium excretion in volume-overloaded patients, according to the ACC/AHA guidelines 2
Potassium supplementation should be stopped immediately in patients receiving it, as recommended by the ACC/AHA guidelines 1